Russ Conroy

Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.

The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.

The progression-free survival end point was not met in the CheckMate -73L trial assessing patients with unresectable stage III non–small cell lung cancer.

Phase 2 data support additional investigation of lifileucel as a treatment for patients with metastatic non–small cell lung cancer.

Treatment with SNB-101 previously demonstrated tolerability among patients with solid tumors in a phase 1 trial.

Phase 2 data support the use of fuzuloparib with or without apatinib in HER2-negative metastatic breast cancer harboring BRCA1/2 germline mutations.

Developers will work with investigators of the phase 3 KEYNOTE-B21 trial to share their findings with the scientific community.

Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.

Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.

Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.

Findings suggest that patients with breast cancer and consistently negative circulating tumor DNA tests tend to have improved clinical outcomes.

Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.

Functional consequences appeared to be lower with HIFU compared with radical prostatectomy in a prospective trial.

Data also highlight a favorable overall survival trend with the acalabrutinib regimen in the phase 3 ECHO trial.

Findings from a health disparities report may support new policies designed to narrow persistent racial and ethnic disparities in health outcomes.

The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.

Phase 3b data support venetoclax as a treatment option in CLL for patients with or without B-cell receptor–associated kinase inhibitor treatment.

Biennial screening mammography is recommended for those who are 40 to 74 years old rather than individualizing screening decisions in this age group.

Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.

Findings from the phase 3 DESTINY-Breast06 trial will be presented at a future medical meeting and shared with regulatory authorities.

Findings from the CheckMate-901 trial support the CHMP’s positive opinion of nivolumab plus chemotherapy in metastatic urothelial carcinoma.

Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.

Findings from the CARTITUDE-2 trial support the use of cilta-cel in patients with multiple myeloma, says Tina Glow, AAS, RN, BSN.

The phase 2b findings support the capability of eftilagimod alpha to enhance the potential of immune checkpoint inhibitors in metastatic HNSCC.

Findings from the phase 3 CARTITUDE-4 trial support the European approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.

The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.

Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.

Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.

A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.